NCT02034110 2023-08-21Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare CancersNovartisPhase 2 Completed206 enrolled 40 charts 2 FDA
NCT01943864 2017-05-31A Phase IIa Study of the MEK Inhibitor Trametinib Monotherapy in the Treatment of Biliary Tract CancersGlaxoSmithKlinePhase 2 Completed20 enrolled 27 charts